source
- Nurix to work with Roche on BTK degrader in pact worth up to $2.3BRoche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B cell malignancies, with broader plans in immunology and neurology. The deal could be ...Endpoints · 1mo ago↗ source
- Innovation alone is no longer enough in biopharmaIn biopharma, the next edge may come from the systems that turn discovery into scale.BioPharma Dive · 1mo ago↗ source
- Precision under pressure: Logistic solutions for nuclear medicine scalabilityRacing the clock: How precision logistics deliver life-saving nuclear medicine.BioPharma Dive · 1mo ago↗ source